Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.66 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.66 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.66 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.66 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.66 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.66 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.66 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.66 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.66 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.66 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.66 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.66 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.66 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.66 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.58 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16528267 | 1.00 | MAPT (0.69) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| SCHEMBL7524534 | 0.98 | HTR1A (0.68) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| SCHEMBL255189 | 0.98 | HTR1A (0.68) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| Bromide SCHEMBL10621563 | 0.97 | HTR1A (0.66) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15938311 | 0.95 | HTR1A (0.64) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL252532 | 0.94 | LMNA (0.61) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| SCHEMBL14984391 | 0.92 | HTR1A (0.61) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| SCHEMBL3805551 | 0.91 | HTR1A (0.61) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| SCHEMBL5805251 | 0.89 | ALDH1A1 (0.58) | MAPTLMNAHTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7302055 | 0.88 | LMNA (0.65) | MAPTLMNAHTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6086661-A | (A)IMIDAZOLINIUM QUATERNARY SALT, (B) PHOSPHONIUM QUATERNARY SALT, OR (C) AN AMMONIUM QUATERNARY SALT; A PAPER-CURL REDUCING COMPOUND; DYE; STABILIZERS, BIOCIDE, WATER SOLUBLE SALT | XEROX CORPORATION (US) | 2000-07-11 | — | — | US | claimed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-2963028-B1 | PIPERAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ATIR HOLDING S A (LU) | 2018-08-01 | — | — | EP | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-9278957-B2 | Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use | ATIR HOLDING S.A. (LU) | 2016-03-08 | — | — | US | disclosed |
| EP-2963028-A1 | PIPERAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Atir Holding S.A. (LU) | 2016-01-06 | — | — | EP | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2938608-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2435414-B1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ATIR HOLDING S A (LU) | 2015-08-19 | — | — | EP | disclosed |
| US-20150099784-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GROEN AERONAUTICS CORPORATION | 2015-04-09 | — | — | US | disclosed |
| US-20020128231-A1 | Aryl-indane compounds | EASTMAN CHEMICAL COMPANY | 2002-09-12 | — | — | US | disclosed |
| US-20020107253-A1 | Novel 4,5,-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2002-08-08 | — | — | US | disclosed |
| WO-2002030915-A2 | ARYL-INDANE COMPOUNDS FOR USE AS INHIBITORS OF P-GLYCOPROTEIN MEDIATED TRANSPORT | AVLAN LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| US-6355642-B1 | PSYCHOLOGICAL DISORDERS AND BRAIN DISORDERS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6086661-A | (A)IMIDAZOLINIUM QUATERNARY SALT, (B) PHOSPHONIUM QUATERNARY SALT, OR (C) AN AMMONIUM QUATERNARY SALT; A PAPER-CURL REDUCING COMPOUND; DYE; STABILIZERS, BIOCIDE, WATER SOLUBLE SALT | XEROX CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5428038-A | Administering for preventing or treating N-methyl-D-aspartate induced convulsions | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1995-06-27 | — | — | US | disclosed |
| US-5162322-A | Anxiolytic agetns; humans, animals | A. H. ROBBINS COMPANY, INCORPORATED (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107253-A1 | Novel 4,5,-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | DRD4, DRD3, DRD2 | HTR1A 208/4885SLC6A2 806/4885SLC6A4 508/4885 |
| US-20150099784-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | DPYD, BRPF3, BRPF1 | HTR1A 721/4885SLC6A2 3298/4885SLC6A4 2292/4885 |
| US-20020128231-A1 | Aryl-indane compounds | ABCB1, ABCC1, ABCG2 | HTR1A 3276/4885SLC6A2 191/4885SLC6A4 202/4885 |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | HTR1A 116/4885SLC6A2 322/4885SLC6A4 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.